epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-214, Phase III. Recruiting
Heart failure with reduced ejection fraction
CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.
Where EPI-214 stands on September 30th 2026
Randomised472of 824 needed
Sites open120of 120 planned
Median forecast finishFeb 2028Deadline Mar 2027
Finish11 months lateMedian forecast at the planned sites and rates, against the sponsor's deadline; the Plan tab shows the sites that would close the gap.Open the plan
Enrolment91% of planRandomised to date against the count the plan expected by now.Open KPIs
Sites60 of 113 behindSites below their own expectation. The colour pools every site against what sites of their kind should recruit, so it changes only when the shortfall is more than chance.Open Sites
KRIs33 of 120 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
QTLs1 of 4 outsideStudy-level quality limits, judged once enough patients are in.Open QTLs
One QTL needs a decision: stopped study treatment early, outside its limit.